Healio
SearchLoading
Healio
SearchLoading
Image of leukemia cells

Take Homes in Leukemia
ByAkriti Jain, MD
ByMarley V. Ghizzone
Fact checked byMindy Valcarcel, MS

Read more

January 18, 2024
4 min watch
Save

VIDEO: Improving response rates, survival with triplet combination therapy in AML

ByAkriti Jain, MD
ByMarley V. Ghizzone
Fact checked byMindy Valcarcel, MS

SAN DIEGO — Akriti Jain, MD, highlights presentations from ASH Annual Meeting and Exposition focused on triplet combination therapy for patients with acute myeloid leukemia.

“At ASH 2023 — and also last year — we’ve been trying to see how we can improve the response rates and survival of patients treated with HMA Ven (venetoclax [Venclexta; Genentech, AbbVie] plus hypomethylating agent therapy),” Jain, a leukemia and myeloid disorders physician at Cleveland Clinic, said.

References:

  • Issa G, et al. Abstract 58. Presented at: ASH Annual Meeting and Exhibition; Dec. 9-12, 2023; San Diego.
  • Yang L, et al. Abstract 55. Presented at: ASH Annual Meeting and Exhibition; Dec. 9-12, 2023; San Diego.
  • Yilmaz M, et al. Abstract 158. Presented at: ASH Annual Meeting and Exhibition; Dec. 9-12, 2023; San Diego.
Sources/Disclosures

Collapse
Source:

Healio Interviews

Disclosures: Jain reports no relevant financial disclosures.

Read more from Take Homes in Leukemia

View all

Read more about

acute myeloid leukemia
cleveland clinic
venetoclax
selinexor
quizartinib
decitabine
 

Related Content